Syndax Pharmaceuticals
SNDX • NASDAQ
Syndax Pharmaceuticals is a biotechnology company in the healthcare sector trading on NASDAQ, led by CEO Michael A. Metzger, with a market cap of $2.1B.
CEOMichael A. Metzger
Next Earnings
Upcoming earnings announcement for Syndax Pharmaceuticals
Date
Monday, May 4, 2026 (in a month)
Timing
After Market Close (4:00 PM New York)
Fiscal Period
Q1 2026
EPS Estimate
-$0.58
Revenue Estimate
$71.8M
Earnings History
Past 12 earnings reports for Syndax Pharmaceuticals
| Date | Period | EPS | EPS Surprise | Revenue | Rev. Surprise | Filing |
|---|---|---|---|---|---|---|
| Feb 26, 2026 | Q4 2025 | -$0.78Est: -$0.60 | -30.0% | $68.7MEst: $63.3M | +8.6% |  10-K |
| Nov 3, 2025 | Q3 2025 | -$0.70Est: -$0.72 | +2.8% | $45.9MEst: $48.3M | -4.9% | 10-Q |
| Aug 4, 2025 | Q2 2025 | -$0.83Est: -$1.00 | +17.0% | $38.0MEst: $27.6M | +37.5% | 10-Q |
| May 5, 2025 | Q1 2025 | -$0.98Est: -$1.27 | +22.8% | $20.0MEst: $16.2M | +23.9% | 10-Q |
| Mar 3, 2025 | Q4 2024 | -$1.10Est: -$1.08 | -1.9% | $7.7MEst: $22.2M | -65.5% | 10-K |
| Nov 5, 2024 | Q3 2024 | -$0.98Est: -$1.11 | +11.7% | $12.5MEst: $11.2M | +11.6% | 10-Q |
| Aug 1, 2024 | Q2 2024 | -$0.80Est: -$0.91 | +12.1% | $3.5M | — | 10-Q |
| May 8, 2024 | Q1 2024 | -$0.85Est: -$0.98 | +13.3% | - | — | 10-Q |
| Feb 27, 2024 | Q4 2023 | -$1.00Est: -$0.99 | -1.0% | - | — | 10-K |
| Nov 2, 2023 | Q3 2023 | -$0.73Est: -$0.78 | +6.4% | - | — | — |
| Aug 3, 2023 | Q2 2023 | -$0.64Est: -$0.73 | +12.3% | - | — | 10-Q |
| May 8, 2023 | Q1 2023 | -$0.59Est: -$0.60 | +1.7% | -Est: $430.0K | -100.0% | — |